HugoScore hugoscore.org

Full review

Counterforce Health CAIHL draft report

Evidence-linked HugoScore draft report for a health AI tool that affects patients.

Back to profile Markdown source

HugoScore CAIHL Draft Report: Counterforce Health

Status: Draft for human review Last reviewed: 2026-06-10 Review method: Public-source review of the official homepage, about page, and privacy policy, plus NBC News, Axios, GrepBeat, and CBS17 coverage confirmed via search; no product walkthrough, vendor interview, corporate-records check, or independent verification of success-rate claims. Service: Counterforce Health Vendor: Counterforce Health, Inc. Category: Coverage appeal AI

Summary

Counterforce Health is a Durham, North Carolina startup that generates free AI appeal letters for denied health insurance claims. Patients upload a denial letter, plan details, and relevant documents, and the system drafts an evidence-based appeal citing clinical literature, billing codes, and plan terms. The company also offers a beta voice AI called Maxwell, free human case management for complex cases, grants for small clinics, and a mobile Appeals on Wheels program for rural areas. It is funded by grants from the NIH and the University of Pennsylvania, is chaired by CareYaya CEO Neal Shah, and publicly commits that the service will always be free for individuals and will never accept money from insurance companies.

From a CAIHL perspective, Counterforce is one of the clearest current examples of algorithmic resistance: AI built for the patient side of an AI-mediated denial system. The free model, the no-insurer-money pledge, and the human case-management layer all point toward patient alignment. The open questions are governance rather than intent. The privacy policy permits training AI models on patient data with de-identification only where feasible, the 70 to 75 percent success claims are self-reported, and the company's corporate structure behind the .org domain is not disclosed on the site.

Evidence Reviewed

CAIHL Profile

  • Who does this AI serve? Patient-directed. Free for individuals, grant-funded, pledged against insurer money, with planned future revenue from clinic subscriptions rather than patients.
  • Can patients tell AI is involved? Yes. AI appeal generation and the Maxwell voice AI are the advertised product.
  • Can patients meaningfully choose? Yes. Use is voluntary, patient-initiated, and free, with human case management as an alternative for complex cases.
  • Can patients correct or challenge what the AI produces? Partial. Letters are drafts the patient submits, and the privacy policy grants access, correction, and deletion rights, but in-app editing workflows were not verified.
  • Does it help patients understand or act? Yes. Appeal letters, rights guidance, voice AI follow-up, reported regulator notifications, rural outreach, and free case management are all action support.

Agency Interpretation

Counterforce's clearest agency value is removing the cost barrier entirely. A patient with a denial letter can get a professional-grade appeal at no charge, and the company pairs the AI with free human help for the hardest cases instead of leaving patients alone with a chatbot. The founders' framing of the denial system as a deliberately adversarial machine is itself CAIHL-style critical reflection, and the reported practice of copying state regulators on appeals turns individual appeals into systemic pressure.

The unresolved tension is data and verification. Patients hand over denial letters and medical context, and the privacy policy allows that data to train the company's AI models, with de-identification promised only where feasible. That is a meaningful secondary use of sensitive data inside an otherwise patient-aligned service, and it is not surfaced in the marketing. The success-rate numbers also vary across the site and press, from 70 percent to 75 percent to 2x the national average, and none are independently audited. Free does not need to mean unexamined.

Key Unknowns

  • Whether Counterforce Health, Inc. is a for-profit company, a nonprofit, or a hybrid, and how its governance relates to CareYaya.
  • Whether patients can opt out of having their appeal data used to train AI models.
  • Which third-party AI providers process patient documents and under what agreements.
  • How the embedded third-party intake form handles uploaded denial letters and medical records.
  • Whether the 70 to 75 percent success claims are measured per appeal, per patient, or per claim value, and over what sample.
  • Whether the HIPAA-compliance badge reflects covered-entity status, a business associate posture, or voluntary alignment.
  • What happens when AI-drafted appeals fail, beyond the free case-management offer.
  • Language access, disability access, and support for patients without internet beyond the mobile clinic pilot.

Publication Recommendation

Ready for human review as a draft profile. Confidence should stay at medium until the corporate and governance structure is verified, the AI-training opt-out question is answered, and at least one success-rate figure is independently checked. The strong patient-alignment signals justify listing now, with the data-training caveat kept visible.